Beactica Therapeutics to present update on LSD1 programme at the AACR Annual Meeting 2023

STOCKHOLM, April 11, 2023 /PRNewswire/ — Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its LSD1 programme has been selected for a poster presentation at the American Association for Cancer Research’s Annual Meeting 2023. The conference will take…